Crowdonomics
All companies

Global Pharma Labs, Inc.

Operating

Biotech · San Leandro, CA

Estimated pre-money ⓘ
$50.5M
As of Dec 2016 · from Reg A Offering (2016) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$54,400
Across 1 round since 2016
Latest share price
$1.00
Reg A+ · Equity · Dec 2016 offering price

Financials

FY2015–FY2023 · from SEC filings · hover any figure for its source
2016
−$89K
2017
−$32K
2018
−$27K
2019
−$22K
2020
−$106K
2021
−$25K
2022
−$32K
2023
RevenueNet income — beside revenue when positive, below the line when a loss

Chart shows the most recent 8 fiscal years; 1 earlier year is in the table below.

Metric
FY2015 audited
FY2016 audited
FY2017 audited
FY2018 audited
FY2019 audited
FY2020 audited
FY2021 audited
FY2022 audited
FY2023 audited
Income statement
Revenue
$0
—
—
—
—
—
—
—
—
Cost of goods sold
$0
—
—
—
—
—
—
—
—
Net income
-$30,163
—
-$88,529
-$32,377
-$27,010
-$22,215
-$106,270
-$25,190
-$31,872
Balance sheet
Cash
$0
$0
$20,988
$28,846
$4,931
$932
$2,103
$4,452
$214
Accounts receivable
$0
—
—
—
—
—
—
—
—
Total assets
$0
$0
$20,988
$28,846
$4,931
$932
$2,103
$4,452
$214
Long-term debt
$0
—
—
—
—
—
—
—
—
Total liabilities
$5,113
$5,113
$12,515
$13,100
$13,695
$31,183
$82,850
$76,063
$96,142
Other
Headcount
0
—
—
—
—
—
—
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$50.5M
est. pre-money
Reg A+ · Equity · Dec 2016

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Aug 31, 2023
ClassOutstandingVotes / shareShare of totalLast price
Common stock50,603,900—100.0%$1.00Dec 2016

Shares outstanding over timein today's share terms

51M25M0
Dec 2016Aug 2019
Common stockRound opened

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $54.4K / $30MEst. pre-money $50.5M

Team

2 people
Sylvester L. Crawford
Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, President, Secretary, Treasurer, Director
Kuo Liang Yang
Chief Medical Officer, Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 1-ZMay 28, 20240001882781-24-000011
    EDGAR
  • Form 1-SADec 29, 20230001690824-23-000013
    EDGAR
  • Form 1-KDec 29, 20230001690824-23-000017
    EDGAR
  • Form 1-USep 8, 20230001883083-23-000018
    EDGAR
  • Form 1-KJan 27, 20230001690824-23-000010
    EDGAR
  • Form 1-KJan 26, 20230001690824-23-000005
    EDGAR
  • Form 1-SAJan 26, 20230001690824-23-000008
    EDGAR
  • Form 1-SASep 28, 20210001675426-21-000012
    EDGAR
Source: SEC EDGARCIK 0001690824DEShare price $1.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.